Results from a polarized Analysis of Safety Data of an adjuvanted Herpes Zoster Subunit Vaccine Candidate consisting of more than 14,500 Study Participants from the Age of 50 Years
Por:
Lopez-Fauqued, M, Campora, L, Delannois, F, El Idrissi, M, Ledent, E, Diez-Domingo, J, McElhaney, J, McNeil, S, De Looze, F, Yeo, W, da Silva, F and Hain, J
Publicada:
1 abr 2018
Categoría:
Internal medicine
Resumen:
Filiaciones:
Lopez-Fauqued, M:
GlaxoSmithKline, Wavre, Belgium
Campora, L:
GlaxoSmithKline, Wavre, Belgium
Delannois, F:
GlaxoSmithKline, Wavre, Belgium
El Idrissi, M:
GlaxoSmithKline, Wavre, Belgium
Ledent, E:
GlaxoSmithKline, Wavre, Belgium
:
Fdn Fomentode Invest Sanitaria & Biomed FISABIO, Valencia, Spain
McElhaney, J:
Hlth Sci North Res Inst, Sudbury, ON, Canada
McNeil, S:
IWK Hlth Ctr, Halifax, NS, Canada
Nova Scotia Hlth Author, Halifax, NS, Canada
De Looze, F:
Univ Queensland, Brisbane, Qld, Australia
Yeo, W:
Univ Wollongong, Wollongong, NSW, Australia
da Silva, F:
GlaxoSmithKline, Wavre, Belgium
Hain, J:
GlaxoSmithKline GmbH & Co KG, Munich, Germany
|